TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2024
Sl No | Company | Q1 | Q2 | Q3 | Total | Best selling products |
1 | JOHNSON AND JOHNSON | $21.8 | $43.8 | $66.1 | $88.8 | Stelara, Darzalex, Imbruvica |
2 | ROCHE | $15.8 | $34.8 | $51.9 | $66.4 | Ocrevus, Perjeta, Tecentriq, Hemlibra, Kadcyla, Alecensa, Mabthera/Rituxan |
3 | PFIZER | $14.9 | $28.2 | $45.9 | $63 | Comirnaty, Paxlovid, Prevenar 13, Ibrance, Eliquis |
4 | MERCK | $14.0 | $28.4 | $43.4 | $57 | Keytruda, Lagevrio, Januvia, Gardasil/Gardasil9 |
5 | ABBVIE | $12.3 | $26.8 | $41.2 | $56 | Skyrizi, Rinvoq, Humira, Imbruvica, Venclexta |
6 | ASTRAZENECA | $12.2 | $24.6 | $39.2 | $54 | Tagrisso, Farxiga, Imfinzi |
7 | NOVARTIS | $11.8 | $24.3 | $37.2 | $50.3 | Entresto, Cosentyx |
8 | BMS | $11.9 | $23.5 | $35.9 | $48.3 | Opdivo, Eliquis, Orencia |
9 | ELI LILLY | $8.8 | $31.5 | $45 | Trulicity, Humalog, Alimta, Taltz | |
10 | SANOFI | $12.4 | $23.2 | $37.4 | $42.6 | Dupixent |
11 | ABBOTT | $10.0 | $20.4 | $31.0 | $42.0 | |
12 | NOVO NORDISK | $9.4 | $28.9 | Ozempic, Victoza, Tresiba, NovoMix, NovoRapid, NovoSeven | ||
13 | GSK | $9.3 | $39.3 | Dolutegravir products, Nucala, Xevudy | ||
14 | TAKEDA | |||||
15 | AMGEN | $33.4 | Prolia, Otezla, Enbrel, Blincyto |
Top pharmaceutical companies by revenues in 2024
1. JOHNSON AND JOHNSON
Q1 REVENUES:
In the first quarter of 2024, Johnson & Johnson reported sales growth of 2.3%, reaching $21.4 billion. The operational growth was 3.9%, and the adjusted operational growth (excluding COVID-19 Vaccine impact) stood at 4.0%. Notably, adjusted operational growth, excluding the vaccine, was an impressive 7.7%.
Q2 REVENUES
In the second quarter of 2024, reported sales increased by 4.3%, reaching $22.4 billion. The company saw an operational growth of 6.6% and an adjusted operational growth of 6.5%.
Excluding the COVID-19 vaccine, global operational sales for Innovative Medicine rose by 8.8%. This growth was primarily driven by products such as Darzalex (daratumumab), Erleada (apalutamide), and other oncology treatments, as well as Tremfya (guselkumab) and Stelara (ustekinumab) in the immunology sector, and Spravato (esketamine) in neuroscience. However, this growth was somewhat offset by declines in other neuroscience products.
Q3 REVENUES
In the third quarter of 2024, Johnson and Johnson reported sales saw an increase of 5.2%, reaching $22.5 billion. Operational growth stood at 6.3%, with adjusted operational growth at 5.4%.
Revenues from innovative medicines amounted to $14.6 billion. Stelara's revenues experienced a decline of 6.6%, totaling $2.68 billion. On the other hand, Tremfya generated $1.0 billion in revenue, reflecting a 13% growth. Darzalex brought in $3.0 billion, marking a significant 21% rise in revenue.
Q4 REVENUES
In 2024, worldwide sales reached to $88.8 billion, reflecting a 4.3% increase from the previous year.
Revenue from innovative medicines reached $57 billion, marking a 4% rise compared to the previous year, while the MedTech sector generated $31.8 billion in revenue.
Best selling drugs
Sl No | Brands | Revenues |
1 | Darzalex | $11.7 billion |
2 | Stelara | $10.4 billion |
2. ROCHE
Q1 RESULTS:
Sales Decline: In the first quarter of 2024, Roche reported a 6% decline in sales, amounting to 14.4 billion Swiss francs (approximately $15.80 billion). This decrease was attributed to the impact of foreign exchange rates and the loss of revenue from COVID-related products.
Pharmaceutical Division: The pharmaceutical division’s performance also slowed, with sales dropping to $11.96 billion from $12.71 billion in the same period last year.
Q3 RESULTS:
Group sales rose by 6% at constant exchange rates (CER) (2% in CHF) in the first nine months, mainly due to strong demand for medicines and diagnostics. Excluding COVID-19-related products, the sales growth reached 8%.
In the third quarter, Group sales showed a 9% increase (6% in CHF), consistent with the growth seen in the second quarter.
The Pharmaceuticals Division saw a 7% rise in sales over the first nine months, with a 9% increase in the base business. This growth was driven by high demand for newer treatments for severe illnesses, with major contributors including Vabysmo (for serious eye conditions), Phesgo (for breast cancer), and Ocrevus (for multiple sclerosis).
Q4 RESULTS:
Roche experienced a 7% increase in total revenue (3% in CHF) in 2024 at constant exchange rates, fueled by strong sales in both therapeutics and diagnostic solutions.
The company reported annual revenue of approximately $69 billion, reflecting steady growth across key segments.
The Pharmaceuticals Division saw an 8% rise in sales, reaching around $52.6 billion. This growth was primarily driven by the continued success of innovative treatments for serious medical conditions.
Best-selling drugs of 2024
Sl No | Brand | Revenues |
1 | Ocrevus | $7.7 billion |
2 | Hemlibra | $ 5.1 billion |
3 | Vabysmo | $4.4 billion |
4 | Tecentriq | $4.1 billion |
5 | Perjeta | $4.1 billion |
3. PFIZER
Q1 RESULTS:
Pfizer reported total revenues of $14.9 billion for Q1 2024.
Q4 RESULTS:
Pfizer posted $17.8 billion in revenue for the fourth quarter of 2024, reflecting a strong 21% operational growth compared to the same period last year.
Pfizer closed 2024 with total revenue of $63.6 billion, showcasing a 7% year-over-year operational growth
Eliquis | $7.3 billion |
Prevanar | $ 6.4 billion |
Paxlovid | $ 5.7 billion |
Ibrance | $ 4.4 billion |
4. MERCK
Q1 RESULTS:
Merck reported continued strong growth in oncology and vaccines. Total worldwide sales for Q1 2024 were $14.0 billion.
Keytruda revenues were $6.9 billion, an increase of 20% revenues compared to previous year.
Keytruda | $6.9 billion |
Gardasil/Gardasil 9 | $2.2 billion |
Also read: AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer
5. ABBVIE
Q1 RESULTS:
AbbVie delivered first-quarter net revenues of $12.310 billion, showing a modest increase of 0.7% on a reported basis and 1.6% on an operational basis.
Q4 RESULTS:
The company reported total net revenues of $56.334 billion for the full year, reflecting a 3.7% growth based on reported figures and a 4.6% rise on an operational basis.
Revenues from the global immunology sector reached $26.682 billion, marking a 2.1% increase in reported terms and a 2.9% increase operationally.
Among key products, Humira generated $8.993 billion in global revenue, while Skyrizi brought in $11.718 billion, and Rinvoq recorded $5.971 billion.
The oncology segment reported global net revenues of $6.555 billion, demonstrating a growth of 10.8% in reported figures and 12.0% operationally. Within this category, Imbruvica accounted for $3.347 billion in revenue, whereas Venclexta contributed $2.583 billion.
Skyrizi | $ 11.7 billion |
Humira | $ 9.0 billion |
Rinvoq | $ 5.7 billion |
6. ASTRAZENECA
Q4 REVENUES
AstraZeneca delivered impressive financial results for 2024, reporting a 21% increase in total revenue, reaching $54.1 billion. Additionally, AstraZeneca achieved nine successful high-value Phase III trial readouts throughout the year, reinforcing its pipeline strength.
The oncology division remained the largest revenue contributor, generating $22.4 billion, a 24% increase compared to the previous year.
AstraZeneca’s BioPharmaceuticals segment recorded $21.9 billion in revenue, reflecting a 21% growth for the year.
The rare disease portfolio experienced a 16% revenue growth in 2024, as demand for key treatments continued to rise.
7. NOVARTIS
Q1 REVENUES
Sales Growth: The company reported a 25% increase in net income from continuing operations, reaching $2.68 billion compared to $2.15 billion in Q1 2023.
Q3 REVENUES
Novartis generated USD 37.1 billion in revenue in the first nine months. The main drivers of this growth were strong sales from Entresto, which reached USD 5.6 billion with a 28% increase overall; Cosentyx, at USD 4.5 billion with a 24% increase; Kesimpta, which achieved USD 2.3 billion, growing by 49%; Kisqali, at USD 2.1 billion with a 45% overall growth.
Q4 REVENUES
Total revenue reached $50.3 billion, reflecting an 11% increase year-over-year (12% at constant currency). Growth was primarily fueled by a 14 percentage-point rise in sales volume, while pricing remained stable. However, competition from generics resulted in a 2 percentage-point decline.
Sl No | Brand | Revenues |
1 | Entresto | $ 7.8 billion |
2 | Cosentyx | $ 6.1 billion |
3 | Kesimpta | $ 3.2 billion |
4 | Kisqali | $3.0 billion |
9. BMS
Q1 REVENUES
In the first quarter, Bristol Myers Squibb reported revenues of $11.9 billion, marking a 5% increase, or 6% when accounting for foreign exchange effects. This growth was primarily fueled by strong performances from Eliquis, Reblozyl, and Opdualag, although somewhat tempered by declines in Opdivo and Revlimid sales.
In the U.S., revenues rose by 7% to $8.5 billion, driven by the success of Eliquis, Reblozyl, and Opdualag, offsetting declines in Revlimid. Opdivo revenues saw a decrease from $1.3 billion to $1.2 billion, down by 10%, mainly due to inventory adjustments and timing of orders, despite underlying demand growth.
Meanwhile, international revenues remained relatively steady at $3.4 billion, as increased demand for Opdivo, Yervoy, and Reblozyl offset lower selling prices. Foreign exchange fluctuations had a 5% adverse impact on revenues.
10. SANOFI
Q1 REVENUES
Sanofi achieved a 6.7% sales growth at constant exchange rates (CER), with net sales totaling $12.4 billion. Dupixent revenues were $3.4 billion, and expected revenues were $14.0 billion.
Q3 REVENUES
Sanofi reported total revenue of approximately $44.5 billion in Q4. Dupixent has outperformed expectations, surpassing its $14 billion target for 2024. The medication is expected to sustain its momentum with robust sales in both existing and newly approved treatments.
Beyfortus achieved remarkable success in its first complete year on the market, generating $1.85 billion in revenue.
Q4 REVENUES
Sanofi reported total revenue of approximately $44.5 billion.
Dupixent has outperformed expectations, surpassing its $14 billion target for 2024. The medication is expected to sustain its momentum with robust sales in both existing and newly approved treatments.
Beyfortus achieved remarkable success in its first complete year on the market, generating $1.85 billion in revenue.